Shares of cell therapy pioneer Iovance Biotherapeutics (IOVA) have risen by 150% since my March 2019 recommendation suggested that readers accumulate dips ahead of key data catalysts.
Given that performance is negative year to date shares have recently lost their premium valuation due to buyout rumors and, thesis remains quite derisked with prior data sets (for lead indications melanoma and cervical cancer) I decided to revisit with an eye toward 2020 catalysts
Chart
Figure 1: IOVA daily advanced chart (Source: Finviz)
When looking at charts, clarity often comes from taking a look at